
    
      HIV-1-infected, clinically stable, treatment-na√Øve adults who have completed 96-weeks of
      elvucitabine therapy in protocol ACH443-015 and whose HIV RNA levels remain below 50
      copies/mL from the 92-week assessment in protocol ACH443-015 or subjects who have completed
      48-weeks of elvucitabine therapy in protocol ACH443-018 and continue to maintain a HIV-1 RNA
      viral load below their baseline level upon entry into protocol ACH443-018
    
  